Q8003 — Competitive Intelligence Brief

Q8003 (Q8003) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: kappa opioid receptor antagonist. Area: Psychiatry.

phase 3 kappa opioid receptor antagonist kappa opioid receptor Psychiatry Small molecule

Target snapshot

Q8003 (Q8003) — QRxPharma Inc.. Q8003 is a selective inhibitor of the kappa opioid receptor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Q8003 TARGET	Q8003	QRxPharma Inc.	phase 3	kappa opioid receptor antagonist	kappa opioid receptor
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
opioid pain pills	opioid pain pills	Rush University Medical Center	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)
Opioid group	Opioid group	Beijing Friendship Hospital	marketed	Opioid agonist	Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor
Opium tincture	Opium tincture	Asbjørn Mohr Drewes	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)
Diluted Deodorized Tincture of Opium	Diluted Deodorized Tincture of Opium	Eastern Maine Medical Center	marketed	Opioid agonist	Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (kappa opioid receptor antagonist class)

1. Astellas Pharma Inc · 1 drug in this class
2. QRxPharma Inc. · 1 drug in this class